These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9440474)

  • 1. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.
    Simpson HL; Jackson NC; Shojaee-Moradie F; Jones RH; Russell-Jones DL; Sönksen PH; Dunger DB; Umpleby AM
    J Clin Endocrinol Metab; 2004 Jan; 89(1):425-32. PubMed ID: 14715881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I).
    Cheetham TD; Connors M; Clayton K; Watts A; Dunger DB
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):415-24. PubMed ID: 9196603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus.
    Cheetham TD; Clayton KL; Taylor AM; Holly J; Matthews DR; Dunger DB
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):515-22. PubMed ID: 8187319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.
    Hartman ML; Clayton PE; Johnson ML; Celniker A; Perlman AJ; Alberti KG; Thorner MO
    J Clin Invest; 1993 Jun; 91(6):2453-62. PubMed ID: 8514857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM.
    Carroll PV; Umpleby M; Ward GS; Imuere S; Alexander E; Dunger D; Sönksen PH; Russell-Jones DL
    Diabetes; 1997 Sep; 46(9):1453-8. PubMed ID: 9287046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Acerini CL; Watts A; Holly JM; Dunger DB
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3686-91. PubMed ID: 11502796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM; Hartman ML; Pieper KS; Skiles EH; Pezzoli SS; Hintz RL; Thorner MO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats.
    Böni-Schnetzler M; Hauri C; Zapf J
    Diabetologia; 1999 Feb; 42(2):160-6. PubMed ID: 10064095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM; Hartman ML; Pezzoli SS; Harrell FE; Hintz RL; Alberti KG; Thorner MO
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.
    Bianda TL; Hussain MA; Keller A; Glatz Y; Schmitz O; Christiansen JS; Alberti KG; Froesch ER
    Diabetologia; 1996 Aug; 39(8):961-9. PubMed ID: 8858219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.
    Pal BR; Phillips PE; Matthews DR; Dunger DB
    Diabetologia; 1992 Jun; 35(6):542-9. PubMed ID: 1612227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus.
    Cheetham TD; Taylor A; Holly JM; Clayton K; Cwyfan-Hughes S; Dunger DB
    J Endocrinol; 1994 Aug; 142(2):367-74. PubMed ID: 7523562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.